09:34 AM EDT, 08/06/2024 (MT Newswires) -- Harmony Biosciences ( HRMY ) reported Q2 adjusted earnings Tuesday of $1.05 per diluted share, compared with $0.76 a year earlier.

Two analysts surveyed by Capital IQ expected $0.12

Net product revenue for the quarter ended June 30 was $172.8 million, compared with $134.2 million a year earlier. Analysts surveyed by Capital IQ expected $172.5 million.

The pharmaceutical company reaffirmed its outlook for 2024 net product revenue of $700 million to $720 million. Analysts surveyed by Capital IQ expect $709.4 million.

Shares of Harmony Biosciences ( HRMY ) were up by nearly 3% in recent trading.

Price: 33.80, Change: +2.88, Percent Change: +9.31